| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 02/06/2002 | CN1334086A Ointment for treating beriberi and ringworm of hand or foot |
| 02/06/2002 | CN1334083A Nitroimiazoles colon target medicine and its preparing process |
| 02/06/2002 | CN1334038A Animal lung product as medicinal food and its preparing process |
| 02/05/2002 | US6344562 Thiazole derivatives |
| 02/05/2002 | US6344546 A receptor protein with a cytoplasmic domain having protein kinase activity, a kinase insert, a transmembrane domain and an extracellular domain having three immunoglobulin-like repeats; for drug screening |
| 02/05/2002 | US6344544 Semaphorin-specific antibodies |
| 02/05/2002 | US6344475 Cystic fibrosis |
| 02/05/2002 | US6344465 Inhibitors of IMPDH enzyme |
| 02/05/2002 | US6344449 Headache and morphine dependence |
| 02/05/2002 | US6344314 Determined DNA sequenced derived from a papillomavirus genome, their uses for in vitro diagnostic purposes and the production of antigenic compositions |
| 02/05/2002 | US6344201 Inhibitors of e. coli and shigella enterotoxins; used for drugs and dna vaccines |
| 02/05/2002 | US6344200 Lactoferrin receptor protein |
| 02/05/2002 | US6344197 Methods for treating sepsis |
| 02/05/2002 | CA2057612C Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof |
| 02/04/2002 | CA2354253A1 Polypeptides or nucleic acids encoding these of a family of g-protein coupled receptors and their use for the diagnosis or treatment of disorders, for example skin disorders and their use for the identification of pharmacologically active substances |
| 01/31/2002 | WO2002008716A2 Method for screening peptides for use in immunotherapy |
| 01/31/2002 | WO2002008449A2 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 01/31/2002 | WO2002008446A2 Synthesis and antiviral evaluation of nucleic acid based (nab) libraries |
| 01/31/2002 | WO2002008435A1 Codon-optimized papilloma virus sequences |
| 01/31/2002 | WO2002008434A2 Bicistronic influenza comprising two genes in tandem |
| 01/31/2002 | WO2002008420A2 A method of down-regulating gene expression |
| 01/31/2002 | WO2002008418A2 Method of isolation of regulated virulence determinants from bacterial pathogens |
| 01/31/2002 | WO2002008396A2 Human proteases |
| 01/31/2002 | WO2002008393A2 Serine protease from yersinia enterocolitica |
| 01/31/2002 | WO2002008292A2 Human monoclonal antibody against hepatitis c virus e2 glycoprotein |
| 01/31/2002 | WO2002008287A2 Nk cells activating receptors and their therapeutic and diagnostic uses |
| 01/31/2002 | WO2002008286A2 Zinc finger domain recognition code and uses thereof |
| 01/31/2002 | WO2002008285A2 Il-17 molecules and uses thereof |
| 01/31/2002 | WO2002008267A2 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/31/2002 | WO2002008264A2 Papillomavirus infected epithelial cells and methods of producing infectious papillomavirus in epithelial cells and uses thereof |
| 01/31/2002 | WO2002008256A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | WO2002008255A2 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | WO2002008251A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | WO2002008244A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | WO2002008241A2 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| 01/31/2002 | WO2002008235A1 Medicament for oral application, containing aminopropyl phosphonic acid esters as an active ingredient |
| 01/31/2002 | WO2002008226A2 Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors |
| 01/31/2002 | WO2002008224A1 Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| 01/31/2002 | WO2002008219A2 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 01/31/2002 | WO2002008217A2 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| 01/31/2002 | WO2002008204A2 5-substituted pyrimidine derivatives of conformationally locked nucleoside analogues |
| 01/31/2002 | WO2002008198A2 Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | WO2002008197A1 Biphenyl carboxamides |
| 01/31/2002 | WO2002008195A1 Pyrazolyl biphenyl carboxamides and the use thereof for controlling undesired microorganisms |
| 01/31/2002 | WO2002008189A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | WO2002008187A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | WO2002008185A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | WO2002007769A1 A method of stabilisation and compositions for use therein |
| 01/31/2002 | WO2002007764A1 Improvements relating to vaccines containing bordetella pertussis antigen |
| 01/31/2002 | WO2002007763A2 Helicobacter pylori with modified lipopolysaccharide biosynthesis |
| 01/31/2002 | WO2002007760A2 Therapeutic agent against aids comprising anti hiv goat antibody |
| 01/31/2002 | WO2002007744A1 Essential oil combination and therapeutic uses thereof |
| 01/31/2002 | WO2002007742A2 Bacteriophage having multiple host range |
| 01/31/2002 | WO2002007730A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | WO2002007729A1 Non-sedating barbiturate compounds as neuroprotective agents |
| 01/31/2002 | WO2002007721A2 Use of cox-2 inhibitors for preventing immunodeficiency |
| 01/31/2002 | WO2002007720A1 Compounds having mif antagonist activity |
| 01/31/2002 | WO2002007712A2 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
| 01/31/2002 | WO2002007683A1 Antimicotic nail varnish composition |
| 01/31/2002 | WO2002007533A2 Nutritional composition |
| 01/31/2002 | WO2002007516A2 Uses for nad synthetase inhibitors |
| 01/31/2002 | WO2001070668A3 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 01/31/2002 | WO2001070172A3 Solid, water-dispersible, oral pharmaceutical form comprising rifampicin, isoniazid and pyridoxine hydrochloride, method for obtaining and presenting said pharmaceutical form |
| 01/31/2002 | WO2001066519A3 Method for preparing pyrimidone derivatives with antifungal activity |
| 01/31/2002 | WO2001064244A3 In ovo protection against infectious bronchitis |
| 01/31/2002 | WO2001060832A3 Pluraflavins and derivatives thereof, process for their preparation and use thereof |
| 01/31/2002 | WO2001053322A3 Aerothricin analogs, their preparation and use |
| 01/31/2002 | WO2001052894A3 Nasally administrable cyclic peptide compositions |
| 01/31/2002 | WO2001052887A3 Vaccination against canine herpesvirus infection and vaccines |
| 01/31/2002 | WO2001042457A3 Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s prnas and their uses |
| 01/31/2002 | WO2001040473A3 Pseudomonas aeruginosa antigens |
| 01/31/2002 | WO2001038503A3 Novel human protein kinases and protein kinase-like enzymes |
| 01/31/2002 | WO2001036605A3 2786, a human aminopeptidase |
| 01/31/2002 | WO2001034801A3 Recombinant gelatin in vaccines |
| 01/31/2002 | WO2001034177A3 Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
| 01/31/2002 | WO2001008634A3 Polynucleotide encoding a human serine protease |
| 01/31/2002 | WO2000064487A8 Delivery of antimicrobial toxins |
| 01/31/2002 | WO2000057910A9 Attenuated dengue-4 virus vaccine |
| 01/31/2002 | WO2000034261A3 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group |
| 01/31/2002 | US20020013662 Pharmacokinetic-based drug design tool and method |
| 01/31/2002 | US20020013480 Methods for preparing antiviral calanolide compounds |
| 01/31/2002 | US20020013354 p38 map kinase inhibitors |
| 01/31/2002 | US20020013349 Administering drug which opens potassium channel for reducing pain |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013341 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition |
| 01/31/2002 | US20020013337 For therapy of respiratory disorder including adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis or chronic sinusitis |
| 01/31/2002 | US20020013334 HMG-CoA reductase inhibitors and method |
| 01/31/2002 | US20020013333 As inhibitors of matrix metalloproteinase, for therapy of diseases such as degenerative diseases and certain cancers |
| 01/31/2002 | US20020013322 Novel compounds for enhancing chemotherapy |
| 01/31/2002 | US20020013316 Nitrogen-containing heterocyclic carboxamide derivatives or salts thereof and antiviral agents comprising the same |
| 01/31/2002 | US20020013287 Nucleosides, nucleoside analogs, abasic nucleosides, or heterocyclic derivatives linked by a phophodiester, a phosphorothioate or phosphonate group; sustained release; anticarcinogenic agents, viricides and microbiocides |
| 01/31/2002 | US20020013281 11,12-Dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L -ribohexopyranosyl)oxy) 6-0-methyl 3-oxo-12,11-(oxycarbonyl) ((4-(4-(4-aminophenyl)-1H-imidazol-1-yl)-butyl)imino))-erythromycin; grampositive bacteria, esp. staphyloccus |
| 01/31/2002 | US20020013278 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 01/31/2002 | US20020013270 Administering a microbiocide to inhibit or eliminate at least one symptom of the disorder; also using a probiotic mixture including a replenishing gastrointestinal microbe; anxiolytic agents; autism; psychosis; attention deficit |
| 01/31/2002 | US20020013256 Novel inhibitors of formation of advanced glycation endproducts (AGES) |
| 01/31/2002 | US20020012906 Method for kidney disease treatment by drug intervention |
| 01/31/2002 | US20020012706 Method of making granular pharmaceutical vehicle |
| 01/31/2002 | US20020012696 In gene therapy and in in vitro and in vivo transfection |
| 01/31/2002 | US20020012672 For immunization of domestic fowl, such as turkeys and chickens, against E. coli infections (Colibacillosis) |
| 01/31/2002 | US20020012668 Used in diagnostics, detection of the bacteria Salmonella.typhi or in the production of vaccines for typhoid fever |